Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma (MM) survival is improving with novel agents.
• MM remains incurable, with resistant clones causing frequent relapses.
• Recent approvals of novel agents complicate relapsed MM management.

Purpose of the Study:

• To provide updated guidelines for diagnosing and treating relapsed multiple myeloma.
• To offer evidence-based decision trees for managing patients with relapsed MM.
• To address the complexities of relapsed MM in the era of novel therapies.

Main Methods:

• Systematic review of evolving literature on MM biology and therapy.
• Development of diagnostic evaluation recommendations.
• Creation of treatment decision trees for relapsed MM stages.

Main Results:

• Guidelines for diagnostic evaluation of relapsed MM.
• Decision trees for treatment selection in relapsed MM.
• Evidence supporting the recommendations and decision trees.

Conclusions:

• Optimal care for relapsed multiple myeloma requires careful consideration of disease evolution and prior therapies.
• Updated guidelines and decision trees are crucial for managing complex relapsed MM cases.
• Ongoing evaluation of novel agents and treatment strategies is essential for improving patient outcomes.